Papers/PMID:40510020
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Obesity reviews : an official journal of the International Association for the Study of Obesity2025The record
4 findings · 1 compound · 4 endpoints · 2 null
What it reported
How to read these marksWhat moved
2 findings
tirzepatide — decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Additionally, once‐weekly tirzepatide resulted in decreases in BMI and waist circumference, with MDs of −5.89 kg/m2 (95% CI: −8.97 to −2.81, p = 0.0002) (Figure S1A) and −12.31 cm (95% CI: −13.93 to −10.68, p < 0.0001) (Figure S1B), respectively.”
Quoted verbatim from Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg or maximum tolerated dose, once weekly
- Population
- Adults with overweight or obesity without diabetes, six placebo-controlled randomised trials
Effect -5.89 mean difference, 95% CI -8.97 to -2.81
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40510020Permalink
tirzepatide — decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Compared with placebo, once‐weekly tirzepatide led to a substantial decrease in the percentage change in body weight, with an MD of −16.32% and a 95% CI of −18.35 to −14.29 (p < 0.0001).”
Quoted verbatim from Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg or maximum tolerated dose, once weekly
- Population
- Adults with overweight or obesity without diabetes, six placebo-controlled randomised trials of 18 to 88 weeks (five phase 3 SURMOUNT trials and one phase 1 trial)
Effect -16.32 mean difference, 95% CI -18.35 to -14.29
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40510020Permalink
What did not
2 findings
tirzepatide — no detected effect on serious adverse event incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Despite the side effects associated with tirzepatide, the RR for serious adverse events with once‐weekly tirzepatide compared with placebo was 0.93 (95% CI: 0.76–1.13, p = 0.45), which was not statistically significant.”
Quoted verbatim from Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg or maximum tolerated dose, once weekly
- Population
- Adults with overweight or obesity without diabetes, six placebo-controlled randomised trials
Effect 0.93 risk ratio, 95% CI 0.76 to 1.13
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40510020Permalink
tirzepatide — no detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Similarly, the RR for mortality showed no significant difference between tirzepatide and placebo (RR: 0.65, 95% CI: 0.28–1.51, p = 0.32).”
Quoted verbatim from Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg or maximum tolerated dose, once weekly
- Population
- Adults with overweight or obesity without diabetes, six placebo-controlled randomised trials of 18 to 88 weeks
Effect 0.65 risk ratio, 95% CI 0.28 to 1.51
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40510020Permalink